Latest Articles

Per- and polyfluoroalkyl substances (PFAS) are widely used and persist in the environment and the human body for extended periods. Technology Networks invited Dr. Carol Kwiatkowski to an Ask Me Anything session to answer your questions about PFAS and their impact on human health.

Leukaemia UK recently announced that it will channel £600,000 into four new AML research projects. Technology Networks spoke to Kate Nash, research communications manager at Leukaemia UK, to learn more about the innovative research projects aiming to improve the treatment of AML.

Bayesian statistics has emerged as a powerful methodology for making decisions from data in the applied sciences. Bayesian brings a new way of thinking to statistics, in how it deals with probability, uncertainty and drawing inferences from an analysis.

The gene therapy landscape is dynamic and constantly shifting. In this article, we will review major advances in disease modification for illnesses that presently still lack effective treatments, as well as some challenges and approaches to overcome them.

Scientists have demonstrated the potential for using intratumoral microdevices (IMDs) to test various cancer drugs on the tumor before implementing systemic treatment. The approach could offer a hope in tackling hard-to-treat gliomas.

This article explores the current state of drug monitoring and highlights the important role precision dosing can play in optimizing patient care.

Explore the current state of decentralization in cell therapy manufacturing as well as the challenges and future technologies that may define the space.

A recent study found that over one-third of men aged 15 years and over are infected with at least one type of HPV. In this article, we explore why HPV is not just a women's health issue.

Proteomics methods are now applied across a variety of scientific disciplines. In this article, we explore just some of the recent trends and advancements in high-throughput and single-cell proteomics.

Regulatory guidance relating to analytical procedures is in the process of changing to a lifecycle approach to ensure that procedures are suitable for intended use across all phases of the drug development life cycle.